Cidara Therapeutics (CDTX) EPS (Weighted Average and Diluted): 2018-2025
Historic EPS (Weighted Average and Diluted) for Cidara Therapeutics (CDTX) over the last 6 years, with Sep 2025 value amounting to -$3.10.
- Cidara Therapeutics' EPS (Weighted Average and Diluted) fell 26.53% to -$3.10 in Q3 2025 from the same period last year, while for Sep 2025 it was -$10.62, marking a year-over-year increase of 60.02%. This contributed to the annual value of -$26.82 for FY2024, which is 367.25% down from last year.
- Cidara Therapeutics' EPS (Weighted Average and Diluted) amounted to -$3.10 in Q3 2025, which was down 87.88% from -$1.65 recorded in Q2 2025.
- Cidara Therapeutics' EPS (Weighted Average and Diluted)'s 5-year high stood at $0.60 during Q1 2023, with a 5-year trough of -$20.65 in Q2 2024.
- In the last 3 years, Cidara Therapeutics' EPS (Weighted Average and Diluted) had a median value of -$2.28 in 2024 and averaged -$3.78.
- The largest annual percentage gain for Cidara Therapeutics' EPS (Weighted Average and Diluted) in the last 5 years was 322.22% (2023), contrasted with its biggest fall of 1,362.50% (2023).
- Quarterly analysis of 5 years shows Cidara Therapeutics' EPS (Weighted Average and Diluted) stood at -$0.28 in 2021, then surged by 32.14% to -$0.19 in 2022, then slumped by 521.05% to -$1.18 in 2023, then crashed by 256.78% to -$4.21 in 2024, then dropped by 26.53% to -$3.10 in 2025.
- Its EPS (Weighted Average and Diluted) was -$3.10 in Q3 2025, compared to -$1.65 in Q2 2025 and -$1.66 in Q1 2025.